Literature DB >> 28034646

2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A2 inhibitors.

Anneta Smyrniotou1, Maroula G Kokotou2, Varnavas D Mouchlis3, Efrosini Barbayianni4, George Kokotos4, Edward A Dennis5, Violetta Constantinou-Kokotou6.   

Abstract

Calcium-independent phospholipase A2 (GVIA iPLA2) has recently attracted interest as a medicinal target. The number of known GVIA iPLA2 inhibitors is limited to a handful of synthetic compounds (bromoenol lactone and polyfluoroketones). To expand the chemical diversity, a variety of 2-oxoamides based on dipeptides and ether dipeptides were synthesized and studied for their in vitro inhibitory activity on human GVIA iPLA2 and their selectivity over the other major intracellular GIVA cPLA2 and the secreted GV sPLA2. Structure-activity relationship studies revealed the first 2-oxoamide derivative (GK317), which presents potent inhibition of GVIA iPLA2 (XI(50) value of 0.007) and at the same time significant selectivity over GIVA cPLA2 and GV sPLA2.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dipeptides; Inhibitors; Oxoamides; Phospholipase A(2); Pseudodipeptides

Mesh:

Substances:

Year:  2016        PMID: 28034646      PMCID: PMC5291822          DOI: 10.1016/j.bmc.2016.12.007

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  32 in total

1.  Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2.

Authors:  David A Six; Efrosini Barbayianni; Vassilios Loukas; Violetta Constantinou-Kokotou; Dimitra Hadjipavlou-Litina; Daren Stephens; Alan C Wong; Victoria Magrioti; Panagiota Moutevelis-Minakakis; Sharon F Baker; Edward A Dennis; George Kokotos
Journal:  J Med Chem       Date:  2007-08-02       Impact factor: 7.446

Review 2.  Calcium-independent phospholipase A2 and apoptosis.

Authors:  Jesús Balsinde; Rebeca Pérez; María A Balboa
Journal:  Biochim Biophys Acta       Date:  2006-08-03

3.  Pancreatic islets express a Ca2+-independent phospholipase A2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin.

Authors:  Z Ma; S Ramanadham; K Kempe; X S Chi; J Ladenson; J Turk
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

4.  Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates.

Authors:  Varnavas D Mouchlis; Denis Bucher; J Andrew McCammon; Edward A Dennis
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

Review 5.  Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.

Authors:  Wei-Yi Ong; Tahira Farooqui; George Kokotos; Akhlaq A Farooqui
Journal:  ACS Chem Neurosci       Date:  2015-05-01       Impact factor: 4.418

Review 6.  Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).

Authors:  Victoria Magrioti; George Kokotos
Journal:  Expert Opin Ther Pat       Date:  2013-01-08       Impact factor: 6.674

Review 7.  Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.

Authors:  Victoria Magrioti; George Kokotos
Journal:  Expert Opin Ther Pat       Date:  2010-01       Impact factor: 6.674

8.  Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages.

Authors:  J Balsinde; E A Dennis
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

9.  Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2).

Authors:  George Kokotos; Stavroula Kotsovolou; David A Six; Violetta Constantinou-Kokotou; Christopher C Beltzner; Edward A Dennis
Journal:  J Med Chem       Date:  2002-07-04       Impact factor: 7.446

10.  Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β): candidate drug for preventing beta-cell apoptosis and diabetes.

Authors:  Tomader Ali; George Kokotos; Victoria Magrioti; Robert N Bone; James A Mobley; William Hancock; Sasanka Ramanadham
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

View more
  1 in total

Review 1.  Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.

Authors:  Aikaterini Nikolaou; Maroula G Kokotou; Sofia Vasilakaki; George Kokotos
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-23       Impact factor: 4.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.